Tumor samples used to create lab models for drug testing
NCT ID NCT06782451
First seen Jun 27, 2026 · Last updated Jul 21, 2026 · Updated 2 times
Summary
This study takes tumor samples from 50 patients with specific gene mutations to grow tiny 3D cell clusters called spheroids in the lab. These spheroids help researchers test how well new or existing cancer drugs work against tumors with those mutations. The samples are collected during routine biopsies or surgeries, and the study does not provide direct treatment to participants.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 50 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
May 2025
- Expected to finish
-
Jul 2030
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age 18 years or older. * Patient for whom at least one mutation deemed of interest by the investigator has been identified. * Patient with a malignant tumor at a locally advanced or metastatic stage, for whom a tissue tumor sample (via surgery, radiology, or endoscopy) is scheduled as part of their standard care. * Tumor volume deemed sufficient by the physician to ensure an adequate amount of material for analysis by the pathologist and the transfer of a part of the tumor sample to the Laboratory of Translational Research in Oncology for the study. * INR \< 1.5; Platelets \> 50,000/μL. * Patient who has been informed of the study and has signed the informed consent form. * Patient affiliated with a social security insurance. Exclusion Criteria: * Patient with multiple primary malignant tumors. * Patient with a known HIV, Hepatitis C, or Hepatitis B infection. * Patient on: * Clopidogrel (hydrogensulfate) or Prasugrel (hydrochloride) or Ticlopidine (hydrochloride) with no possibility of suspension for 5 days, * Low molecular weight heparin with no possibility of dose suspension before the procedure, * Fondaparinux with no possibility of suspension, * Abciximab with no possibility of suspension for 24 hours and aPTT \< 50s and ACT \< 150s, * Eptifibatide or Tirofiban Hydrochloride Monohydrate or Argatroban with no possibility of suspension 4 hours before the procedure, * Bivalirudin with no possibility of suspension 2-3 hours if CrCL \>50 mL/min or 3-5 hours if CrCL \<50 mL/min before the procedure, * Dabigatran etexilate with no possibility of suspension 2-3 days if CrCL \>50 mL/min or 3-5 days if CrCL \<50 mL/min before the procedure. * Patient considered vulnerable; vulnerable persons are defined in articles L1121-5 to L1121-8: * Pregnant women, parturients, and breastfeeding mothers, * Individuals deprived of their liberty by a judicial or administrative decision, individuals hospitalized without consent under articles L. 3212-1 and L. 3213-1 who do not fall under the provisions of article L. 1121-8, and individuals admitted to a healthcare or social facility for reasons other than research, * Adults under legal protection or unable to express their consent.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Neoplasm malignant are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Centre Antoine Lacassagne
RECRUITINGNice, 06189, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a 10-Week lifestyle program boost fitness after cancer?
- Can adding immunotherapy to standard cancer care be safe for indian patients?
- Can a new nucleotide analogue boost cancer treatment?
- Could a simple blood test replace invasive tissue biopsies for cancer genetics?
- Experimental drug targets tough blood cancers in first human trial
- New Antibody-Drug conjugate STRO-002 tested in advanced cancers